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ABSTRACT
Objectives: To assess the prevalence of Hashimoto 
thyroiditis (HT) in primary thyroid lymphoma (PTL) 
and whether it differs between mucosa-associated lymphoid 
tissue (MALT) lymphoma and diffuse large B-cell 
lymphoma (DLBCL).
Methods: Electronic databases were searched for studies 
assessing HT prevalence in PTL, based on antithyroid 
antibodies, clinical history, or pathology. Pooled prevalence 
of HT and its association with histotype (MALT or 
DLBCL) were calculated.
Results: Thirty-eight studies with 1,346 PTLs were 
included. Pooled prevalence results were 78.9% (any HT 
evidence), 65.3% (antithyroid antibodies), 41.7% (clinical 
history), and 64% (pathology). HT prevalence was 
significantly higher in MALT lymphoma than in DLBCL 
(P = .007) and in mixed DLBCL/MALT than in pure 
DLBCL (P = .002).
Conclusions: Overall, 78.9% of patients with PTL have 
any HT evidence, but only half of these had been clinically 
followed. The difference in HT prevalence suggests that a 
subset of DLBCL may not derive from MALT lymphoma.
Primary thyroid lymphoma (PTL) is a rare malig-
nancy that accounts for 1% to 5% of all thyroid malignan-
cies and 1% to 7% of all extranodal lymphomas.1-4 PTL 
occurs preferentially in females, with an incidence peak in 
the seventh decade.1,4,5 The most common clinical presen-
tation of PTL is a palpable mass in the neck, which may 
cause dysphagia, dyspnea, and hoarseness. In addition, 
B symptoms (fever, night sweats, and weight loss of 10% 
and higher in the past 6 months) can be present.1
The most common histotypes are diffuse large B-cell 
lymphoma (DLBCL), which accounts for 50% to 70% of 
cases, and mucosa-associated lymphoid tissue (MALT) 
lymphoma, which accounts for 10% to 50% of cases.6 
Follicular lymphoma, small lymphocytic lymphoma, 
Burkitt lymphoma, mantle cell lymphoma, T-cell lym-
phoma, and Hodgkin lymphoma have been described less 
commonly.1
The most important risk factor for PTL is Hashimoto 
thyroiditis (HT), which causes a 40- to 80-fold increase in 
the risk of PTL.3 However, it is unclear whether HT is a 
necessary condition for the development of PTL. In fact, 
while some authors suggested that all PTLs originate in 
an HT setting, other authors reported no evidence of HT 
in a series of patients with PTL.2,3,7-9 Moreover, it is also 
unclear whether HT is associated with particular PTL 
histotypes more strongly than with other ones.
Aims of this study were (1) to define the prevalence 
of HT in patients with PTL, based on the several different 
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diagnostic criteria adopted (eg, positive antithyroid anti-
bodies, clinical history, histologic evidence) and (2) to as-
sess the association of HT with PTL histotypes.
Materials and Methods
Methods of this review followed those from pre-
vious studies.10,11 The study methods were defined before 
the beginning of the study. All stages of the review were 
performed independently by three authors (A.T., M.P., 
and M.M.). Disagreements were resolved by consensus 
among authors. The study was reported by following the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement.12
Search Strategy and Study Selection
Six electronic databases (MEDLINE, Scopus, Web of 
Sciences, OVID, Cochrane Library, and Google Scholar) 
were searched from January 2009 to December 2018 for 
studies assessing the presence of HT in patients with PTL. 
The following combination of text words was used: (primary 
OR primitive) AND thyroid AND lymphoma. Exclusion 
criteria were as follows: data not extractable, inclusion of 
only T-cell PTLs, inclusion of only Hodgkin PTL, language 
other than English, case reports, and reviews.
Data Extraction
Data were not modified during extraction. Primary 
extracted data were the number of patients with HT and 
the total number of patients with PTL. The variable 
“number of patients with HT” was categorized based 
on the methods for HT diagnosis as follows: presence of 
antithyroid antibodies, clinical history of HT, histologic 
evidence of HT, and overall prevalence of HT diagnosed 
by any method.
The variable “total number of patients with PTL” 
was also categorized based on the histologic type of lym-
phoma as follows: MALT or DLBCL. Moreover, wherever 
possible, data on DLBCL were subdivided into DLBCL 
with the MALT-type component and pure DLBCL.
Risk of Bias Within Study Assessment
A modified version of the revised Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS-2)13 was used 
to assess the risk of bias within studies. Four domains re-
lated to the risk of bias were assessed: (1) patient selection 
(ie, if  the patients were selected consecutively or if  at least 
inclusion criteria and period of enrollment were reported), 
(2) HT diagnosis (“index test” in the original QUADAS-2; 
ie, if  methods for HT diagnosis were clearly described, 
(3) PTL diagnosis (“reference standard” in the original 
QUADAS-2; ie, if  the results were subdivided according 
to the histotype of PTL), and (4) flow (ie, if  all PTLs were 
assessed for the presence of HT). Authors’ judgments were 
categorized as “low risk,” “high risk,” or “unclear risk of 
bias,” as previously described.14,15 Concerns about applica-
bility were also assessed for the “patient selection” domain 
(ie, if  methods for patient selection did not suit the aim of 
our review, regardless of their correctness).
Data Analysis
The prevalence of HT in PTL was calculated as 
the number of patients diagnosed with HT by the total 
number of PTL patients. A  subgroup analysis was also 
performed based on the time of publication (until 2010 or 
after 2010). The association of HT with the PTL histotype 
was assessed by using the odds ratio (OR). Both HT prev-
alence and OR were calculated for each study and as a 
pooled estimate with a 95% confidence interval (CI), as 
well as reported graphically on forest plots. The random-
effect model of DerSimonian-Laird was used to pool 
data. Statistical heterogeneity was quantified by using 
Higgins’s inconsistency index (I2) and categorized as null 
(I2 = 0%), minimal (0 < I2 ≤ 25%), low (25% < I2 ≤ 50%), 
moderate (50% < I2 ≤ 75%), or high (I2 > 75%), as previ-
ously described.16,17
Review Manager 5.3 (The Nordic Cochrane Centre, 
Cochrane Collaboration, 2014)  and Comprehensive 
Meta-Analysis (Biostat) were used for the analyses.
Results
Study Selection and Characteristics
Thirty-eight studies1-3,6-9,18-28 with a total of  1,346 
PTLs were included, while 21 studies were excluded 
(inclusion of  only T-cell PTL or only Hodgkin PTL; 
unavailability of  data on HT). The process of  study se-
lection is reported in Supplementary Figure 1 (all sup-
plemental materials can be found at American Journal 
of Clinical Pathology  online). The diagnosis of  HT 
was performed based on clinical history in 14 studies, 
on antithyroid antibodies in 15 studies, on histologic 
features in 12 studies, and on sonographic features in 
two studies. In 16 studies, HT diagnosis was based on 
the presence of  at least one criterion among several 
ones. Characteristics of  the included studies are re-
ported in ❚Table 1❚.1-3,6-8,18-48 Data about HT subdivided 
according to each diagnostic criterion are reported in 
Supplementary Table 1.
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Risk of Bias Assessment
For the “patient selection” domain, one study was 
considered at unclear risk of bias (it was unclear whether 
patients were consecutively selected), while all the other 
studies were considered at low risk (all reported at least 
inclusion criteria and period of enrollment). Concerns 
about applicability were raised for eight studies (inclusion 
of only MALT,6,32,38 only DLBCL,27,33,35,43 only interme-
diate/high-grade PTLs19). For the “HT diagnosis” domain, 
the risk of bias was unclear for eight studies7,26,34,37,38,41,47,48 
(unclear methods for HT diagnosis) and low for all the 
remaining studies. For the “PTL diagnosis” domain, the 
risk of bias was unclear for 12 studies2,19,22,23,31,34,36,37,40,44,45,47 
(results not subdivided according to PTL histotype) and 
low for all the remaining studies. For the “flow” domain, 
the risk of bias was unclear for seven studies22,28,31,33,37,39,44 
(presence of HT not assessed on all PTLs) and low for all 
the remaining studies. Results of the risk of bias assess-
ment are reported in Supplementary Figure 2.
HT Prevalence
Among patients with PTL, the overall prevalence 
of HT (ie, the presence of at least one among several 
different diagnostic criteria) was 78.8% (95% CI, 66%-
87.7%; ❚Figure 1❚), with high statistical heterogeneity 
among studies (I2 = 83.530). The percentage of patients 
with positive antithyroid antibodies was 65.3% (95% CI, 
52.3%-76.3%; ❚Figure 2❚), with moderate heterogeneity 
(I2  =  61.347%). The percentage of patients with a clin-
ical history of HT was 41.7% (95% CI, 27.8%-57.1%; 
❚Figure 3❚), with high heterogeneity (I2  =  76.481%). The 
percentage of patients with histologic evidence of HT was 
64% (95% CI, 44.4%-79.8%; ❚Figure 4❚), with high hetero-
geneity (I2 = 87.878%).
❚Table 1❚ 
General Characteristics of the Included Studies
Study Country Period of Enrollment Sample Size, No.
1999 Lam et al18 Hong Kong 1968-1997 23
2000 Derringer et al3 United States 1985-1993 107
2001 Belal et al19 Arabia 1975-1995 52
2002 Thieblemont et al20 France 1987-2000 26
2003 Kim et al21 Korea 1994-2001 9
2003 Lerma et al22 Spain 1992-2001 7
2005 Gupta et al23 India 1998-2004 10
2006 Cho et al24 Korea 1989-2004 18
2006 Sato et al25 Japan 1989-2004 58
2007 Colović et al26 Serbia 1994-1999 9
2007 Niitsu et al27 Japan 1998-2005 32
2007 Au et al9 China 1992-2002 9
2008 Moshynska and Saxena28 Canada 1995-2000 20
2009 Avenia et al29 Italy 1986-2008 6
2009 Hwang et al30 Korea 1991-2006 44
2010 Sun et al31 China 1991-2007 40
2011 Lee et al32 Korea 1997-2007 7
2011 Mian et al33 Multicenter 1985-2006 48
2011 Onal et al34 Multicenter 1986-2006 87
2011 Watanabe et al35 Japan 1990-2004 171
2012 Alzouebi et al36 United Kingdom 1970-2010 70
2012 Nam et al37 Korea 1995-2010 16
2012 Oh et al38 Korea 1989-2010 27
2013 Cha et al39 Korea 1994-2012 29
2013 Kumar et al7 India 2005-2010 16
2014 Ma et al40 China 2002-2008 39
2014 Watanabe et al41 Japan 2005-2011 43
2014 Xia et al8 China 1995-2010 27
2015 Chai et al42 Korea 2000-2013 38
2015 Knief et al43 Germany Unclear 21
2015 Li et al44 China 2007-2014 27
2015 Wang et al2 China 2007-2013 13
2015 Wei et al45 China 2009-2012 20
2015 Yang et al46 China 1995-2012 12
2017 Bostancı et al1 Turkey 2009-2015 11
2017 Gu et al47 China 1999-2017 27
2018 Li et al48 China 2008-2017 20
2018 Watanabe et al6 Japan 1990-2009 107
Total   1,346
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Subgroup Analysis
The overall prevalence of  HT was 71% (95% CI, 
55.8%-82.7%) in the studies published until 2010 and 
82.8% (95% CI, 67.3%-91.8%) in the studies published 
after 2010 (Supplementary Figure 3). The percentage of 
patients with positive antithyroid antibodies was 67.9% 
(95% CI, 50.6%-81.3%) in the studies published until 
2010 and 62.7% (95% CI, 40.4%-80.6%) in the studies 
published after 2010 (Supplementary Figure 4). The 
percentage of  patients with a clinical history of  HT 
was 51.1% (95% CI, 31.1%-70.8%) in the studies pub-
lished until 2010 and 30.9% (95% CI, 15.2%-52.8%) in 
the studies published after 2010 (Supplementary Figure 
5). The percentage of  patients with histologic evidence 
of  HT was 60.2% (95% CI, 37.6%-79.2%) in the studies 
published until 2010 and 73.1% (95% CI, 31.3%-94.2%) 
in the studies published after 2010 (Supplementary 
Figure 6).
Au et al9
❚Figure 1❚ Forest plot reporting the prevalence of Hashimoto thyroiditis in patients with primary thyroid lymphoma based on 
the presence of any diagnostic criterion. CI, confidence interval.
Au et al9
❚Figure 2❚ Forest plot reporting the prevalence of Hashimoto thyroiditis in patients with primary thyroid lymphoma based on 
the positivity for antithyroid antibodies. CI, confidence interval.
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HT in PTL Histotypes
Among PTL, the prevalence of HT was signifi-
cantly higher in MALT lymphoma than in DLBCL, with 
an OR of 2.175 (95% CI, 1.238-3.821; P =  .007; ❚Figure 
5❚), with low statistical heterogeneity among studies 
(I2 = 19.295%). Furthermore, among DLBCL, the prev-
alence of HT was significantly higher in DLBCLs with a 
MALT-type component than in pure DLBCLs, with an 
OR of 9.11 (95% CI, 2.313-35.879; P = .002; ❚Figure 6❚), 
with null heterogeneity (I2 = 0.000%).
Discussion
Main Findings and Interpretation
This study showed that, among patients with PTL, 
65.3% had positive antithyroid antibodies, 41.7% had a 
clinical history of HT, 64% had histologic evidence of 
HT, and 78.9% had any evidence of HT. Furthermore, 
HT prevalence was significantly higher in MALT lym-
phoma than in DLBCL and in DLBCLs with a MALT-
type component than in pure DLBCLs.
Au et al9
❚Figure 3❚ Forest plot reporting the prevalence of Hashimoto thyroiditis in patients with primary thyroid lymphoma based on 
the clinical history. CI, confidence interval.
Au et al9
❚Figure 4❚ Forest plot reporting the prevalence of Hashimoto thyroiditis in patients with primary thyroid lymphoma based on 
the presence of histologic features. CI, confidence interval.
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The diagnosis of HT is based on clinical features, 
serum antithyroid antibodies, sonographic features, and 
pathologic examination.
Clinical features include local manifestations due 
to mass effect and variable systemic manifestations due 
to hypothyroidism. The main antithyroid antibodies are 
antithyroperoxidase antibodies, which constitute the most 
reliable serologic marker of HT, and antithyroglobulin 
antibodies. Ultrasonographic features consist of a loss 
of echogenicity of the thyroid parenchyma, which ap-
pears similar to the surrounding muscles. A characteristic 
pathologic feature is the presence of an interstitial infil-
trate, which is mainly constituted of lymphocytes organ-
ized into true lymphoid follicles.49
The association between HT and PTL is well estab-
lished. Patients with HT bear a 40- to 80-fold increased 
risk of PTL. However, the prevalence of HT in patients 
with PTL is highly variable among the studies in the liter-
ature.2,3,7-9 These differences might be due to the different 
methods used to ascertain the presence of HT. In fact, pa-
tients with HT not necessarily show all sign and symptoms 
of disease,49 and thus it is possible that the prevalence may 
vary based on the criterion adopted for diagnosis.
Our results showed that the overall prevalence of HT 
in PTL was 78.9%. Diagnostic parameters suitable for the 
meta-analysis were presence of antithyroid antibodies, 
clinical history of HT, and histologic evidence of HT; un-
fortunately, only two studies adopted ultrasonographic 
criteria to diagnose HT,8,40 not allowing a meta-analysis. 
As expected, the prevalence of HT according to each 
single parameter was lower than the overall prevalence. 
However, while the percentage of patients with antithyroid 
antibodies was similar to those with pathologic features 
of HT (65.3% and 64%, respectively), a clinical history 
Au et al9
❚Figure 5❚ Forest plot reporting the odds ratio for the association of Hashimoto thyroiditis with mucosa-associated lymphoid 
tissue lymphoma. CI, confidence interval.
❚Figure 6❚ Forest plot reporting the odds ratio for the association of Hashimoto thyroiditis with the presence of a mucosa-
associated lymphoid tissue component in diffuse large B-cell lymphoma. CI, confidence interval.
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of HT was definitely less common (41.7%). In the in-
cluded studies, “clinical history of HT” included any past 
evidence that led to a diagnosis of HT. Our results indi-
cate that about four-fifths of patients with PTL have a 
background of HT, but in half  of these patients HT had 
not been diagnosed previously. It remains to be defined 
whether an improvement in thyroid screening programs 
may also improve prevention of PTL.50,51
In the subgroup analyses about time of  publication, 
we found an increase of  the overall prevalence of  HT 
over time, which was also observed with regard to histo-
logic features. On the other hand, a decrease was found 
for the percentage of  patients with a clinical history of 
HT, while the percentage of  patients with antithyroid 
antibodies appeared relatively stable. However, none of 
these differences was statistically significant, as indicated 
by the widely overlapping 95% CI. Furthermore, the pe-
riod of  enrollment of  the studies did not reflect the time 
of  publication; for example, the study by Gupta et al,23 
published in 2005, enrolled patients since 1998, while the 
newer study by Alzouebi et al,36 published in 2012, en-
rolled patients since 1970. Therefore, it is unclear if  these 
findings reflect a real variation in the prevalence of  HT 
over time.
Regarding histotypes, PTL is in most cases a MALT 
lymphoma or a DLBCL. The association between marginal 
zone lymphomas and autoimmune disorders is well de-
scribed. It is thought that the chronic stimulation of B cells 
caused by autoantigens leads to an increased risk of cumu-
lative genetic events; the activation of the nuclear factor–κB 
pathway seems to be crucial in this process.52 According to 
several authors, almost all cases of PTLs are MALT type, 
which arise from HT and can progress to DLBCL. Based 
on this hypothesis, PTL might be considered a single entity 
with a homogeneous etiopathogenesis.25 In the stomach, 
clonal relationships and identical light chain restrictions 
were found in DLBCL and MALT lymphoma, suggesting 
that most if  not all DLBCLs derive from an evolution of 
MALT lymphomas.53,54 In the thyroid, such a hypothesis 
is also supported by the relatively common finding of a 
MALT-type component coexistent with DLBCL.3,18,20,24,42 
According to our results, among PTLs an HT background 
was significantly less common in DLBCL than in MALT 
lymphoma; furthermore, the prevalence of HT was signifi-
cantly lower in pure DLBCL than in DLBCL with a MALT 
component. Such a finding may suggest that at least a part 
of primary thyroid DLBCL has an etiopathogenesis dif-
ferent from MALT lymphomas. A previous study found 
that VH immunoglobulin family usage was different be-
tween MALT lymphomas and DLBCL of the thyroid,25 
supporting the hypothesis of a different pathogenesis. 
Further studies are necessary in this regard.
Strengths and Limitations
To our knowledge, this is the first meta-analysis as-
sessing the prevalence of HT in PTL. Furthermore, this 
may also be the first review that considered separately the 
different methods for diagnosing HT in this field.
The main limitation to our results might be the sta-
tistical heterogeneity among studies. This heterogeneity 
may in part be due to the different aims of the included 
studies. Some studies are in fact centered on pathology, 
while other ones are focused on clinical features, imaging 
techniques, or treatment outcomes. Although we tried to 
limit this heterogeneity by assessing separately the dif-
ferent diagnostic methods for HT, statistical heteroge-
neity remained significant.
The lack of definitive pathology specimens for many 
patients may be another limitation. The assessment of 
histologic features might indeed be inaccurate on small 
biopsy specimens. However, surgery is recommended 
only for low-grade lymphoma at stage IE-IIE, while high-
grade lymphomas and advanced lymphomas are treated 
with chemo/radiotherapy.55
Finally, a subgroup analysis based on geographic 
differences was not feasible, due to the unbalanced geo-
graphic distribution of the included studies. In fact, most 
of the included studies were from East Asia, while only 
six were from Europe and only two from North America.
Conclusion
Among patients with PTL, 78.9% show any evidence 
of HT, 65.3% have positive antithyroid antibodies, 64% 
have histologic evidence of HT, and only 41.7% have a 
clinical history of HT. HT is significantly less common 
in DLBCL than in MALT lymphoma, suggesting 
that a subset of DLBCLs may not derive from MALT 
lymphomas.
Corresponding author: Antonio Travaglino, MD; antonio.
travaglino.ap@gmail.com.
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